According to a new report, published by KBV research, The Global Guillain-Barre Syndrome Market size is expected to reach $852.2 million by 2030, rising at a market growth of 4.6% CAGR during the forecast period.
The Plasma Exchange segment is anticipating a CAGR of 5% during (2023 - 2030). Plasma exchange, also known as plasmapheresis, effectively reduces disease severity, shortens recovery time, and improves functional outcomes in GBS patients. Clinical studies have demonstrated that plasma exchange can rapidly remove pathogenic antibodies and inflammatory mediators from circulation, thereby mitigating nerve damage and facilitating nerve regeneration.
The Parenteral segment is leading the Global Guillain-Barre Syndrome Market by Route of Administration in 2022; thereby, achieving a market value of $524 million by 2030. Parenteral approaches, particularly intravenous delivery, have a high bioavailability, which means that a greater percentage of the drug is absorbed into the bloodstream. This ensures optimal therapeutic levels of medications, such as immunoglobulins or immunomodulatory agents, necessary for modulating the immune response and promoting recovery in GBS patients.
Retail Pharmacies segment would register a CAGR of 4.8% during (2023 - 2030). Retail pharmacies offer convenient access to medications used in GBS management, including prescription medications, over the counter (OTC) products, and medical supplies. Patients and caregivers can easily obtain GBS-related medications, such as pain relievers, antipyretics, and supportive therapies, from retail pharmacies without needing a hospital visit.
Full Report: https://www.kbvresearch.com/guillain-barre-syndrome-market/
The North America region dominated the Global Guillain-Barre Syndrome Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $295.7 million by 2030. The Europe region is experiencing a CAGR of 4.4% during (2023 - 2030). Additionally, The Asia Pacific region would exhibit a CAGR of 5.1% during (2023 - 2030).
By Therapeutics
By Route Of Administration
By Distribution Channel
By Geography
Unique Offerings 
